ArticleAlzheimer's & dementia (New York, N. Y.)2020

A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study.

Harald Hampel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.